OCULAR THERAPEUTIX, INC

OCUL · Nasdaq · United States

Share price · OCUL

$5.94-5.07 (-46.05%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.7M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when OCUL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Oct 2026-8.4%
  2. 28 Sep 2026-20.7%
  3. 10 Sep 2026-7.4%

    Nothing announced by OCUL that day or the session before.

  4. 8 Sep 2026+6.9%

    Nothing announced by OCUL that day or the session before.

  5. 11 Aug 2026+5.6%
  6. 16 Jul 2026-8.0%

    Nothing announced by OCUL that day or the session before.

  7. 2 Mar 2026+22.8%
  8. 20 Feb 2026+10.7%

    Nothing announced by OCUL that day or the session before.

  9. 17 Feb 2026-21.3%
  10. 8 Dec 2025+28.1%

Share of unusual movement by asset

For each asset, the share of OCUL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Axitinib intravitreal implant (OTX-TKI)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—35%
Sessions with no dated event—58%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Glucocorticoid receptorSmall molecule
Allergic ConjunctivitisOcular Inflammation
Ocular Inflammation and Pain
Phase 3
VEGF receptors + PDGF receptorsSmall molecule
Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Axitinib intravitreal implant (OTX-TKI)Phase 3Neovascular Age-related Macular Degeneration
Est. primary completion 2027-01-08 · NCT06495918 · CT.gov ↗
What to watch
March 2027 (1)
Axitinib intravitreal implant (OTX-TKI)Phase 3Non-Proliferative Diabetic Retinopathy
Est. primary completion 2027-03 · NCT07235085 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Axitinib intravitreal implant (OTX-TKI)Phase 3Neovascular Age-Related Macular Degeneration (nAMD)
Est. primary completion 2030-08-01 · NCT07516132 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 February 2026Topline resultOTX-TKISOL-1 Phase 3 topline: AXPAXLI superiority primary endpoint met
OCULAR THERAPEUTIX, INC · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$13M$75M$532M$95M-$66M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$13M$54M$600M$79M-$67M operating cash flowreport ↗
2026-Q1$11M$66M$668M$89M-$66M operating cash flowreport ↗
2025-Q3$15M$52M$346M$69M-$51M operating cash flowreport ↗
2025-Q2$13M$51M$393M$68M-$55M operating cash flowreport ↗
2025-Q1$11M$43M$351M$64M-$45M operating cash flowreport ↗
2024-Q3$15M$37M$429M$36M-$37M operating cash flowreport ↗
2024-Q2$16M$29M$461M$44M-$25M operating cash flowreport ↗
2024-Q1$15M$21M$485M$65M-$34M operating cash flowreport ↗
2023-Q3$15M$15M$112M$0.5M-$7.7M operating cash flowreport ↗
2023-Q2$15M$15M$68M$21M-$20M operating cash flowreport ↗
2023-Q1$13M$15M$81M$30M-$20M operating cash flowreport ↗
2022-Q3$12M$14M$123M$24M-$13M operating cash flowreport ↗
2022-Q2$12M$13M$136M$19M-$11M operating cash flowreport ↗
2022-Q1$13M$13M$147M$13M-$19M operating cash flowreport ↗
2021-Q3$12M$13M$181M—-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$52M$197M$739M$66M-$205M operating cash flowreport ↗

Ocular Therapeutix reported full-year 2025 revenue of $51.95M, down 18.5% YoY, with R&D spend of $197.1M, up 54.4% YoY. Cash and equivalents were $738.67M, and the company reported a net loss of $265.94M.

The company said SOL-1 Phase 3 superiority data remain masked and are expected to be presented at the 49th Macula Society Annual Meeting; pending positive results, it plans to submit an NDA for AXPAXLI in wet AMD based on 52-week data. SOL-R completed randomization of 631 subjects in December 2025, with topline data accelerated to 1Q 2027; HELIOS-3 is underway, and SOL-X initiation is expected in 2Q 2026. Management guided that current cash supports operations into 2028, after raising approximately $475M gross (about $445.6M net) in a September 2025 equity offering.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$64M$128M$394M$48M-$135M operating cash flowreport ↗
2023-FY$58M$61M$198M$20M-$70M operating cash flowreport ↗
2022-FY$51M$53M$104M$18M-$60M operating cash flowreport ↗
2021-FY$44M$50M$166M$1.6M-$66M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($461K), 29 sales ($3.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Sherif Riad · directorAward / grant28,000——Form 4
2026-11-06Sherif Riad · directorAward / grant (derivative)88,000——Form 4
2026-11-05Saroj Namrata · Chief Business OfficerOpen-market sale35,370$6.55$232KForm 4
2026-10-08Anderman Todd · Chief Legal OfficerOpen-market sale11,984$7.29$87KForm 4
2026-10-02Heier Jeffrey S. · Chief Scientific OfficerOpen-market sale10,869$7.05$77KForm 4
2026-10-02Kaiser Peter · Chief Development OfficerOpen-market sale9,990$7.05$70KForm 4
2026-08-31Notman Donald · Chief Operating OfficerOpen-market sale1,099$10.24$11KForm 4
2026-08-25Dugel Pravin · director, See RemarksGift50,092——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 266 reporting institutions held 206.6M shares ($1.7B, 93.9% of shares outstanding).

#InstitutionSharesValue
1FMR LLC32,653,764$276.6M
2Deep Track Capital, LP19,686,282$166.7M
3BlackRock, Inc.16,132,931$136.6M
4Avoro Capital Advisors LLC12,315,000$104.3M
5Summer Road LLC11,879,825$100.6M
6Venrock Adviser, LLC10,346,926$87.6M
7VANGUARD CAPITAL MANAGEMENT LLC8,719,039$73.9M
8ALLIANCEBERNSTEIN L.P.4,129,687$50.1M
9Point72 Asset Management, L.P.5,534,985$46.9M
10STATE STREET CORP4,708,419$39.9M
11GEODE CAPITAL MANAGEMENT, LLC4,529,185$38.4M
12Logos Global Management LP3,850,000$32.6M
13Octagon Capital Advisors LP3,166,600$26.8M
14Balyasny Asset Management L.P.2,692,622$22.8M
15Commodore Capital LP2,575,000$21.8M